
The study investigated the effects of empagliflozin on patients with acute myocardial infarction (AMI). Out of 6610 screened participants, 6522 were randomized to empagliflozin or placebo alongside standard care. The majority were male (75.1%), with comorbidities like hypertension (69.1%) and type 2 diabetes (31.7%). 74.3% had ST-elevation myocardial infarction. Results will unveil empagliflozin's benefits and risks in AMI patients, shedding light on post-heart attack treatment strategies.
Like
Save
Share